UCB SA (OTCMKTS:UCBJY – Get Free Report) crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $95.03 and traded as high as $95.64. UCB shares last traded at $94.71, with a volume of 5,059 shares.
UCB Trading Down 0.4 %
The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The business has a fifty day moving average price of $95.03 and a two-hundred day moving average price of $86.55.
UCB Company Profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Further Reading
- Five stocks we like better than UCB
- Transportation Stocks Investing
- Dave & Buster’s: Is It Time to Make Another Play on This Stock?
- What Are Growth Stocks and Investing in Them
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- What Investors Need to Know to Beat the Market
- Texas Instruments: The Old-School Tech Titan Still Delivering
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
